Brief: IMAC Holdings Initiates Third And Final Cohort Of Its Phase 1 Clinical Study Of Umbilical Cord-Derived Mesenchymal Stem Cells
24/03/2022 12:34
March 24 (Reuters) - IMAC Holdings Inc IMAC.O :
* IMAC HOLDINGS, INC. ANNOUNCES INITIATION OF THIRD AND
FINAL
COHORT OF ITS PHASE 1 CLINICAL STUDY OF UMBILICAL CORD-DERIVED
MESENCHYMAL STEM CELLS FOR TREATMENT OF BRADYKINESIA DUE TO
PARKINSON'S DISEASE
Source text for Eikon: ID:nGNX7TBlVm
Further company coverage: IMAC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Imac Holdings
See all newsBrief: Nasdaq To Suspend Imac Holdings Stock Trading On March 26, 2025
Imac Holdings Inc Reports Results For The Quarter Ended September 30: Earnings Summary
Brief: Imac Holdings Inc - Regains Compliance With Nasdaq Audit Committee Rule
Imac Holdings Inc Reports Results For The Quarter Ended June 30: Earnings Summary
Brief: IMAC Holdings Enters Agreement To Issue 4,676 Shares Of Series G Preferred Stock